PUBLIC COMPANY
save$DNLIDenali Therapeutics Inc.
$DNLI20.00-2.58%South San Francisco, CA, USupdated 2d ago
community read0 votes
🐶 often sniffed alongside
top 4pipeline
3
marketed
1
phase 3
0
catalysts ytd
3
approvals ytd
1
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 21Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase1A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
- phase3An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
- phase1A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
- phase2Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
- phase1A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
- phase2A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
- phase2Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
- phase2A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
🐶 Hiring Signal
News
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 6d ago
- AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeoverIn the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with good symptom control.biospace · 6d ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 18d ago
- Reeling from past failures, Parkinson's pipeline enters 'era of diversification'While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…biospace · 27d ago
- Denali climbs past Avlayah expectations with $3.6M in revenueAfter launching in April, Hunter syndrome drug Avlayah surprised analysts with a strong first quarter, as patients rush to get access to Denali Therapeutics’ new option.biospace · 1mo ago
- Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storeWith so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.biospace · 2mo ago
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsThe study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.biopharma_dive · 2mo ago
- Pfizer CFO to step down; Denali sells a regulatory fast-passA search is underway for a successor to Dave Denton, who took a job outside the pharmaceutical industry. Elsewhere, a new kind of Duchenne gene therapy got venture backing and a GSK deal paid divid…biopharma_dive · 3mo ago
- Fierce Biotech Fundraising Tracker '26: TriGemX tacks on $94M; AnaCardio adds $71MThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 9mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that